Safety and PK of WCK 5107 alone and with Cefepime in healthy volunteers

Phase 1, randomised, double-blind trial of zidebactam in bacterial infection (3 arms), sponsored by Wockhardt. Primary endpoints: Number of adverse events at 14 days and Measure of laboratory parameters at 14 days. Started Aug 2015; status: completed.